Latest News
Featured News
Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Notice of Interim Results and Presentation
MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial
Result of 2023 Annual General Meeting
Update on SCOPE trial
Scancell presents positive data from the first stage in its Phase 2 SCOPE trial at the 20th International Congress of the Society for Melanoma Research
Scancell announces late-breaking abstract presenting positive data from the first stage in its Phase 2 SCOPE trial
No results found.
Regulatory News Archive
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.